Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices as of Previous Day Close

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 55.56 - Change: -2.4 - Change %: -4.1408
04/17/2024 16:09:00 EST

Crispr Therapeutics AG (CRSP)

Industry: Biotechnology

Price Support Resistance

In the past 20 trading days, CRSP has been trading in a range between $74.50 and $60.67 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

The AI powered stock chart is in a Red zone currently. We would avoid this stock.

Upside / Downside Potential

Crispr Therapeutics AG $CRSP entered a Red zone 16 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $88.13, a potential upside of 58.62% from the recent price of 55.56. Our AI powered stock target predictor currently has a target price of $-38.62 a potential move of -170%. The stock is trading 63.97% (potential upside) below its 52 week high of $91.10 and 47.96 % (potential downside) above its 52 week low of $37.55 - based on the recent price.

Company Summary

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

CRSP Website


Bullish Trendline Has Never Failed Crispr Therapeutics Stock
Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10.
Source: Schaeffers Research
Wed, 17 Apr 2024 12:58:45 -0400
Sentiment: Positive
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Source: Zacks Investment Research
Wed, 17 Apr 2024 10:01:11 -0400
Sentiment: Positive
3 Magnificent Stocks That Could Double or More by 2030
CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.
Source: The Motley Fool
Sat, 13 Apr 2024 08:47:00 -0400
Sentiment: Positive
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.
Source: InvestorPlace
Thu, 11 Apr 2024 13:10:22 -0400
Sentiment: Positive
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 10, 2024 11:45 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Gil Blum - Needham & Company Gil Blum Good morning, everyone, and thank you for joining us on the Third Day of the Needham Healthcare Conference. My name is Gil Blum and I am a Senior Biotech Analyst with a focus on immune oncology.
Source: Seeking Alpha
Wed, 10 Apr 2024 15:25:24 -0400
Sentiment: Neutral
Instituions Institution %: 65.706
Last QTR Institution change: 529122

Insiders %: 1.348
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 203992
Insiders Net last QTR: -203992

Analyst Ratings
Target Price: 88.13
Overall Rating: 3.6897
Strong Buys (5): 10
Buys (4): 5
Holds (3): 11
Sells (2): 1
Strong Sells (1): 2

52 Week Hi: 91.1
52 Week Low: 37.55
Beta: 1.743
50 Day MA: 73.3334
200 Day MA: 59.5007

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 33533.332
Forward PE: 23.3645
Trailing PE: 0

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.